Cerexa is an innovation driven, biopharmaceutical company focused on discovering‚ developing and commercializing a growing portfolio of novel anti–infective therapies for the treatment of serious and life–threatening infections. Cerexa initiated operations in July 2005 and was acquired by Forest Laboratories in January 2007.

Cerexa’s lead product candidate‚ ceftaroline acetate‚ is a next–generation‚ broad-spectrum‚ injectable cephalosporin‚ which combines the advantages of an enhanced gram–positive spectrum‚ including bactericidal anti–MRSA activity‚ with broad gram–negative activity‚ while maintaining the favorable safety profile of cephalosporins.

In May of 2004 single dose Phase 1 studies were initiated to assess the safety and tolerability of ceftaroline in healthy volunteers. These studies were successfully completed in September 2004. Based on these results‚ an Investigational New Drug (IND) application was filed with the FDA in December 2004.

A Phase 2 trial of ceftaroline for the treatment of complicated skin and skin–structure infections (cSSSI) was initiated in October 2005 and patient enrollment was completed in April 2006. The Phase 2 study evaluated the efficacy and safety of ceftaroline versus standard therapy in 100 patients recruited from over 20 investigational centers worldwide.  Ceftaroline achieved excellent clinical and microbiological response rates in this study and was very safe and well tolerated.

Cerexa initiated two Phase 3 trials in cSSSI in February 2007.

At Cerexa we conduct our business with the highest moral and ethical standards. We believe that our ability to positively impact people’s health and save lives is directly linked with the quality of our employees and how we treat each other. We promote an environment that rewards and recognizes achievement. We believe in hard work‚ working together and sharing rewards.